Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 4

1(33.3%)

N/A

1(33.3%)

3Total

Phase 2(1)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04543890Phase 2Unknown

A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC

Role: collaborator

NCT01402232Unknown

REduction of rIsk for Contrast Induced Nephropathy

Role: collaborator

NCT02549963Phase 4Unknown

Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban

Role: collaborator

NCT02403791Not ApplicableCompleted

Point-of-Care Bedside Lung Ultrasound Examination Advanced Trial Protocol

Role: collaborator

NCT01399203Unknown

Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention

Role: collaborator

All 5 trials loaded